Brescia, Italy
Brescia, Italy

Time filter

Source Type

News Article | November 28, 2016
Site: globenewswire.com

ROME, Nov. 28, 2016 (GLOBE NEWSWIRE) -- The Electronic Components and Systems for European Leadership (ECSEL) Joint Undertaking announced the Lab4MEMS project as the winner of its 2016 Innovation Award during the European Nanoelectronics Forum, in Rome, Italy. At its launch in January 2014, Lab4MEMS was identified as a Key Enabling Technology Pilot-Line project for next-generation Micro-Electro-Mechanical Systems (MEMS) devices augmented with advanced technologies such as piezoelectric or magnetic materials and 3D packaging to enhance the next generation of smart sensors, actuators, micro-pumps, and energy harvesters. These technologies were recognized as important contributors to future data-storage, printing, healthcare, automotive, industrial-control, and smart-building applications, as well as consumer applications such as smartphones and navigation devices. In accepting the award, Roberto Zafalon, General Project Coordinator of Lab4MEMS and the European Programs Manager in R&D and Public Affairs for STMicroelectronics Italy said, "The ECSEL Innovation Award highlights the excellent results the Lab4MEMS team achieved through the project's execution and the high impact of its successes. In particular, Lab4MEMS developed innovative MEMS solutions with advanced piezoelectric and magnetic materials, including advanced 3D Packaging technologies." In coordinating the €28m[1], 36-month Lab4MEMS project, ST led the team of twenty partners, which included universities, research institutions, and technology businesses across ten European countries. ST's MEMS facilities in Italy and Malta contributed their complete set of manufacturing competencies for next-generation devices, spanning design and fabrication to test and packaging to the project. All of these successes contributed to the Lab4MEMS project and are available to benefit the contributors. These participants were Politecnico di Torino (Italy); Fondazione Istituto Italiano di Tecnologia (Italy); Politecnico di Milano (Italy); Consorzio Nazionale Interuniversitario per la Nanoelettronica (Italy); Commissariat à l'Energie Atomique et aux énergies alternatives (France); SERMA Technologies SA (France); STMicroelectronics Ltd. (Malta); Universita ta Malta (Malta); Solmates BV (Netherlands); Cavendish Kinetics BV (Netherlands); Okmetic OYJ (Finland); VTT (Finland); Picosun OY (Finland); KLA-Tencor ICOS (Belgium); Universitatea Politehnica din Bucuresti (Romania); Instytut Technologii Elektronowej (Poland); Stiftelsen SINTEF (Norway); Sonitor Technologies AS (Norway); BESI GmbH (Austria). [1] The total cost of the project - € 28.2 million - was supported in part by funding from the ECSEL Joint Undertaking and by contributions from each of the respective National agencies: Italy, France, Malta, The Netherlands, Finland, Belgium, Poland, Norway, Austria, Romania. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/58bc7ac2-94f2-4219-b124-e313a3235239


ROME, 01-Dec-2016 — /EuropaWire/ — The Electronic Components and Systems for European Leadership (ECSEL) Joint Undertaking announced the Lab4MEMS project as the winner of its 2016 Innovation Award during the European Nanoelectronics Forum, in Rome, Italy. At its launch in January 2014, Lab4MEMS was identified as a Key Enabling Technology Pilot-Line project for next-generation Micro-Electro-Mechanical Systems (MEMS) devices augmented with advanced technologies such as piezoelectric or magnetic materials and 3D packaging to enhance the next generation of smart sensors, actuators, micro-pumps, and energy harvesters. These technologies were recognized as important contributors to future data-storage, printing, healthcare, automotive, industrial-control, and smart-building applications, as well as consumer applications such as smartphones and navigation devices. In accepting the award, Roberto Zafalon, General Project Coordinator of Lab4MEMS and the European Programs Manager in R&D and Public Affairs for STMicroelectronics Italy said, “The ECSEL Innovation Award highlights the excellent results the Lab4MEMS team achieved through the project’s execution and the high impact of its successes. In particular, Lab4MEMS developed innovative MEMS solutions with advanced piezoelectric and magnetic materials, including advanced 3D Packaging technologies. In coordinating the €28m[1], 36-month Lab4MEMS project, ST led the team of twenty partners, which included universities, research institutions, and technology businesses across ten European countries. ST’s MEMS facilities in Italy and Malta contributed their complete set of manufacturing competencies for next-generation devices, spanning design and fabrication to test and packaging to the project. In accepting the award, Roberto Zafalon, General Project Coordinator of Lab4MEMS and the European Programs Manager in R&D and Public Affairs for STMicroelectronics Italy said, “The ECSEL Innovation Award highlights the excellent results the Lab4MEMS team achieved through the project’s execution and the high impact of its successes. In particular, Lab4MEMS developed innovative MEMS solutions with advanced piezoelectric and magnetic materials, including advanced 3D Packaging technologies.” In coordinating the €28m[1], 36-month Lab4MEMS project, ST led the team of twenty partners, which included universities, research institutions, and technology businesses across ten European countries. ST’s MEMS facilities in Italy and Malta contributed their complete set of manufacturing competencies for next-generation devices, spanning design and fabrication to test and packaging to the project. All of these successes contributed to the Lab4MEMS project and are available to benefit the contributors. These participants were Politecnico di Torino (Italy); Fondazione Istituto Italiano di Tecnologia (Italy); Politecnico di Milano (Italy); Consorzio Nazionale Interuniversitario per la Nanoelettronica (Italy); Commissariat à l’Energie Atomique et aux énergies alternatives (France); SERMA Technologies SA (France); STMicroelectronics Ltd. (Malta); Universita ta Malta (Malta); Solmates BV (Netherlands); Cavendish Kinetics BV (Netherlands); Okmetic OYJ (Finland); VTT (Finland); Picosun OY (Finland); KLA-Tencor ICOS (Belgium); Universitatea Politehnica din Bucuresti (Romania); Instytut Technologii Elektronowej (Poland); Stiftelsen SINTEF (Norway); Sonitor Technologies AS (Norway); BESI GmbH (Austria). [1] The total cost of the project – € 28.2 million – was supported in part by funding from the ECSEL Joint Undertaking and by contributions from each of the respective National agencies: Italy, France, Malta, The Netherlands, Finland, Belgium, Poland, Norway, Austria, Romania.


News Article | November 18, 2016
Site: www.eurekalert.org

Chicago, IL (November 18, 2016) -- Certain medications commonly used to treat heartburn, acid reflux, and ulcers can have damaging effects on the kidneys. The findings come from two studies that will be presented at ASN Kidney Week 2016 November 15¬-20 at McCormick Place in Chicago, IL. Proton pump inhibitors (PPIs) and histamine receptor-2 (H2) blockers are commonly used to reduce gastric acid production. To see if these drugs increase the risk of developing kidney stones, Pietro Manuel Ferraro, MD, MS, PhD (Fondazione Policlinico Universitario A. Gemelli - Catholic University of the Sacred Heart, in Rome, Italy) and his colleagues examined information on 187,330 participants of the Health Professionals Follow-up Study (HPFS) and Nurses' Health Study (NHS) I and II who were initially free of kidney stones. During a follow-up of up to 12 years for PPIs and 26 years for H2 blockers, 3245 symptomatic kidney stones developed. After adjusting for a number of factors such as age, race, body mass index, physical activity, smoking status, comorbidities, use of medications, and intake of nutrients, use of PPIs was associated with a 12% higher risk of developing a kidney stone, and use of H2 blockers with a 13% higher risk. In a subgroup of participants, use of PPIs was associated with lower urinary excretion of calcium, oxalate, citrate, and magnesium, which are components of kidney stones. "Use of PPIs and H2 blockers is associated with a small increase in risk of incident kidney stones. Further studies are needed to confirm our findings and to investigate whether the excess risk is related to a particular type of kidney stones such as those made of calcium oxalate," said Dr. Ferraro. In a second study, Yan Xie, MPH (VA Saint Louis Health Care System) and his colleagues examined current assumptions that chronic kidney disease that may arise after use of PPIs is secondary to incomplete recovery from acute kidney injury (AKI). When the investigators analyzed information in the Department of Veterans Affairs national database on 152,157 users of PPIs or H2 blockers, PPI use was associated with a greater than 30% higher risk of developing CKD or a combined endpoint of kidney failure or more than 50% decline in estimated glomerular filtration rate (a measure of kidney function) compared with H2 blocker use in the absence of AKI. "Reliance on AKI as a marker of potential adverse renal events in those treated with PPI is not sufficient," said Xie "Exercising vigilance in PPI use--even in the absence of AKI--and careful attention to kidney function in PPI users may be a reasonable approach." ASN Kidney Week 2016, the largest nephrology meeting of its kind, will provide a forum for more than 13,000 professionals to discuss the latest findings in kidney health research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2016 will take place November 15-20, 2016 in Chicago, IL. The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies. Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit http://www. or contact us at (202) 640-4660.


ATLANTA--(BUSINESS WIRE)--Nel 2016 la Fondazione Coca-Cola e The Coca-Cola Company hanno donato complessivamente più 106 milioni di dollari a oltre 230 organizzazioni. Tali contributi andranno direttamente a favore della collettività in più di 200 Paesi e territori, ove approssimativamente il 97 per cento delle sovvenzioni è stato destinato alle cause cui The Coca-Cola Company attribuisce priorità, ossia donne, risorse idriche e benessere collettivo.


IRVINE, California--(BUSINESS WIRE)--La Fondazione del Movimento per la sicurezza dei pazienti (Patient Safety Movement Foundation, PSMF) è alquanto orgogliosa di annunciare che Parrish Medical Center di Titusville, Florida, è divenuto il primo ospedale ad impegnarsi ad adottare tutte e 12 le soluzioni perseguibili per la sicurezza dei pazienti (Actionable Patient Safety Solution, APSS) intese ad eliminare i decessi prevenibili di pazienti entro il 2020 (0X2020). Parrish Medical Center si era g


News Article | November 20, 2016
Site: www.sciencedaily.com

Certain medications commonly used to treat heartburn, acid reflux, and ulcers can have damaging effects on the kidneys. The findings come from two studies that will be presented at ASN Kidney Week 2016 November 15¬-20 at McCormick Place in Chicago, IL. Proton pump inhibitors (PPIs) and histamine receptor-2 (H2) blockers are commonly used to reduce gastric acid production. To see if these drugs increase the risk of developing kidney stones, Pietro Manuel Ferraro, MD, MS, PhD (Fondazione Policlinico Universitario A. Gemelli -- Catholic University of the Sacred Heart, in Rome, Italy) and his colleagues examined information on 187,330 participants of the Health Professionals Follow-up Study (HPFS) and Nurses' Health Study (NHS) I and II who were initially free of kidney stones. During a follow-up of up to 12 years for PPIs and 26 years for H2 blockers, 3245 symptomatic kidney stones developed. After adjusting for a number of factors such as age, race, body mass index, physical activity, smoking status, comorbidities, use of medications, and intake of nutrients, use of PPIs was associated with a 12% higher risk of developing a kidney stone, and use of H2 blockers with a 13% higher risk. In a subgroup of participants, use of PPIs was associated with lower urinary excretion of calcium, oxalate, citrate, and magnesium, which are components of kidney stones. "Use of PPIs and H2 blockers is associated with a small increase in risk of incident kidney stones. Further studies are needed to confirm our findings and to investigate whether the excess risk is related to a particular type of kidney stones such as those made of calcium oxalate," said Dr. Ferraro. In a second study, Yan Xie, MPH (VA Saint Louis Health Care System) and his colleagues examined current assumptions that chronic kidney disease that may arise after use of PPIs is secondary to incomplete recovery from acute kidney injury (AKI). When the investigators analyzed information in the Department of Veterans Affairs national database on 152,157 users of PPIs or H2 blockers, PPI use was associated with a greater than 30% higher risk of developing CKD or a combined endpoint of kidney failure or more than 50% decline in estimated glomerular filtration rate (a measure of kidney function) compared with H2 blocker use in the absence of AKI. "Reliance on AKI as a marker of potential adverse renal events in those treated with PPI is not sufficient," said Xie "Exercising vigilance in PPI use -- even in the absence of AKI -- and careful attention to kidney function in PPI users may be a reasonable approach."


OSAKA, Giappone--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) ha annunciato oggi che Takeda sosterrà in via esclusiva la campagna Shot@Life della Fondazione delle Nazioni Unite per la “Vaccinazione globale dei bambini contro il morbillo”. L'iniziativa si propone di fornire il vaccino antimorbillo ad almeno 5,4 milioni di bambini in approssimativamente 40 Paesi in via di sviluppo in Africa, Asia e America Latina nell'arco di un periodo di 10 anni. Il testo originale del pr


News Article | February 15, 2017
Site: www.businesswire.com

IRVINE, California--(BUSINESS WIRE)--Il Dottor Javier Dávila Torres ha annunciato, insieme a 11 funzionari del Messico, al Vertice mondiale sulla sicurezza dei pazienti, la scienza e la tecnologia organizzato dalla Fondazione del Movimento per la sicurezza dei pazienti (Patient Safety Movement Foundation, PSMF) che 25 ospedali hanno sottoscritto un impegno per l'implementazione di processi tesi ad eliminare i decessi di pazienti prevenibili. Inoltre, l’Accademia di chirurgia del Messico, la Federazione degli anestesiologi e il Collegio dei professionisti in materia di qualità delle cure sanitarie dell'Occidente, di Guadalajara e Jalisco sono entrati a far parte della Fondazione come “partner impegnati” condividenti la missione della PSMF.


News Article | February 20, 2017
Site: phys.org

Michelangelo Pistoletto is acknowledged as one of the founding fathers of the Italian Arte Povera contemporary art movement and is widely regarded as one of the most influential artists of his generation. The Arte Povera movement grew throughout Italy between the end of the 1960s and the beginning of the 1970s. Literally meaning 'poor art', this vivid art movement is characterised by its use of found and unconventional materials. Pistoletto's work mainly deals with the subject of the unification of art and everyday life, and his ongoing 'Third Paradise' project, conceived in 2003, envisions a third 'realm' that merges natural and artificial worlds and a society living in harmony with nature. Pistoletto began his cooperation with ESA for the development of the official mission patch of Paolo Nespoli's VITA mission, which includes the artist's symbol of his Third Paradise concept in the artwork designed by ESA for ASI, the Italian space agency. A natural continuation of this cooperation is the brand-new 'Spac3' app, which will allow users to select and combine Paolo's images from space with their own photos. Developed by ESA and ASI in close cooperation with RAM radioartemobile and Cittadellarte-Fondazione Pistoletto, the app will be launched at the same time as Paolo's launch into space later this year. As a user of this Spac3 app, you'll be able to receive the photos taken by Paolo during his mission and then you'll be invited to generate a new image based on six different themes inspired by the UN's sustainable development goals. These themes are: Life on land; Good health and wellbeing; Industry, innovation and infrastructure; Climate action; Life below water, and Sustainable cities and communities. Focusing on one of those themes, you'll create a unique and personal image that is an original combination of Paolo's space image and your Earth-based one. Your combination will be shaped into the Third Paradise symbol and then published as part of a larger interactive artwork by Pistoletto. The VITA mission, provided by ASI through a barter agreement with NASA, will be Paolo's third spaceflight when he is launched later this year as flight engineer on Expeditions 52/53. Paolo's first spaceflight was the two-week Esperia mission on the Space Shuttle STS-120 in 2007. He returned to the Station in 2010 for ESA's 160-day MagISStra mission as part of Expeditions 26/27. Explore further: Vita: next Space Station mission name and logo


IRVINE, California--(BUSINESS WIRE)--La Fondazione del Movimento per la sicurezza dei pazienti (Patient Safety Movement Foundation, PSMF) ha annunciato che l'operatore sanitario internazionale City International Hospital ubicato a Ho Chi Min City, Vietnam, si è impegnato a raggiungere l'obiettivo di PSMF di zero morti prevenibili entro il 2020. City International Hospital si è impegnato ad intraprendere nuovi provvedimenti per prevenire infezioni ospedaliere e migliorare le comunicazioni relative ai trasferimenti durante le transizioni nella prestazione delle cure ai pazienti.

Loading Fondazione collaborators
Loading Fondazione collaborators